|
|
Diagnostic impact of ornithine decarboxylase
in meningiomas
Stenzel W, Rohn G, Miletic H, Radner H, Deckert M, Ernestus RI.
Department of Neuropathology, University of Cologne, Koln,
Germany. w.stenzel@uni-koeln.de
The objective of this study was to investigate whether activity and protein
expression of ornithine decarboxylase (ODC) the metabolism-rate limiting enzyme
of the polyamine biosynthesis, which is involved in the regulation of cellular
growth and differentiation, reflects the distinct histopathologic
characteristics indicative of atypia and anaplasia in meningiomas as well as
their impact in recurrences.
The authors previously evaluated its value as a critical factor of tumor
development in various brain tumors.
Among 152 meningiomas, World Health Organisations (WHO) grade I meningiomas (n =
121) exhibited a low ODC activity, while meningiomas WHO grade II (n = 22) and
WHO grade III (n = 9), respectively, showed a significantly increased ODC
activity.
Recurrent WHO grade I meningiomas exhibited the same low enzyme activity and
immunohistochemical staining index for ODC positive tumor cells as their primary
tumors, whereas raising ODC activity and protein expression in recurrent
meningiomas paralleled malignant transformation.
These results indicate that ODC reflects aggressive growth and malignization in
meningiomas.
Especially in recurrent meningiomas, the determination of its activity and
protein expression by immunohistochemistry may provide a useful diagnostic tool
to recognize malignant progression.
PMID: 15015770 [PubMed - indexed for MEDLINE]
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15015770
|
